The economic burden of psoriasis: a systematic literature review

References

• National Institutes of Health: National Institute of Arthritis and Musculoskeletal and Skin Diseases. What. is psoriasis? Fast facts: an easy-to-read series of publications for the public. NIH; Bethesda, MD, USA: 2009
   Google Scholar
• Langley R, Krueger G, Griffiths C. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64(Suppl 2):ii18-23
   PubMed Web of Science ®Google Scholar
• National Psoriasis Foundation Data. 2004. Available from: www.psoriasis.org
   Google Scholar
• Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133(2):377-85
   PubMed Web of Science ®Google Scholar
• Hazard E, Cherry S, Lalla D, et al. Clinical and economic burden of psoriasis. Manage Care Interface 2006;19(4):20-6
   PubMedGoogle Scholar
• Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007;57(6):963-71
   PubMed Web of Science ®Google Scholar
• Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004: a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006;55(3):490-500
   PubMed Web of Science ®Google Scholar
• Cancer Trends Progress Report – 2007 Update, National Cancer Institute, NIH, DHHS, Bethesda, MD. 2007. Available from: http://progressreport.cancer.gov
   Google Scholar
• Colombo G, Altomare G, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008;4(2):559
   PubMedGoogle Scholar
• Fourcade RO, Benedict A, Black LK, et al. BJU Int 2010;105(1):49-56
   PubMedGoogle Scholar
• Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol 2012;51(12):1432-40
   PubMed Web of Science ®Google Scholar
• Ismaila AS, Sayani AP, Marin M, Su Z. Clinical, economic, and humanistic burden of asthma in Canada: a systematic review. BMC Pulm Med 2013;13(1):70
   PubMedGoogle Scholar
• Crown WH, Bresnahan BW, Orsini LS, et al. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004;20(12):1929-36
   PubMed Web of Science ®Google Scholar
• Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006;212(2):123-7
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41
   PubMed Web of Science ®Google Scholar
• Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55(5):829-35
   PubMed Web of Science ®Google Scholar
• Gerdes S, Zahl V, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2009;220(1):38-43
   PubMedGoogle Scholar
• Schabert VF, Watson C, Joseph GJ, et al. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm 2013;19(8):621-30
   PubMed Web of Science ®Google Scholar
• Feldman S, Evans C, Russell M. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatol Treat 2005;16(1):37-42
   PubMed Web of Science ®Google Scholar
• Raho G, Koleva DM, Garattini L, Naldi L. The Burden of moderate to severe psoriasis. Pharmacoeconomics 2012;30(11):1005-13
   PubMed Web of Science ®Google Scholar
• The Campbell and Cochrane Economics Methods Group (CCEMG), Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre). CCEMG-EPPI-Centre Cost Converter (version 1.4). Available from: http://eppi.ioe.ac.uk/costconversion/default.aspx
   Google Scholar
• Cochrane handbook for systematic reviews of interventions. Version 5.1.0. 2011. Available from: http://handbook.cochrane.org/
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med 2009;151(4):264-9
   PubMed Web of Science ®Google Scholar
• Jenner N, Campbell J, Plunkett A, Marks R. Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol 2002;43(4):255-61
   PubMedGoogle Scholar
• Carrascosa J, Pujol R, Dauden E, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol 2006;20(7):840-5
   PubMed Web of Science ®Google Scholar
• Navarini AA, Laffitte E, Conrad C, et al. Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly 2010;140(5):85
   PubMedGoogle Scholar
• Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006;213(2):102-10
   PubMed Web of Science ®Google Scholar
• Yu AP, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin 2009;25(10):2429-38
   PubMed Web of Science ®Google Scholar
• Chan B, Hales B, Shear N, et al. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg 2009;13(4):192-7
   PubMed Web of Science ®Google Scholar
• Berger K, Ehlken B, Kugland B, Augustin M. Cost of illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005;3(7):511-18
   PubMedGoogle Scholar
• Sohn S, Schöffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006;212(2):137-44
   PubMed Web of Science ®Google Scholar
• Schöffski O, Augustin M, Prinz J, et al. Costs and quality of life in patients with moderate to severe plaque type psoriasis in Germany: a multi center study. J Dtsch Dermatol Ges 2007;5(3):209-18
   PubMedGoogle Scholar
• Driessen R, Bisschops L, Adang E, et al. The economic impact of high need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 2010;162(6):1324-9
   PubMed Web of Science ®Google Scholar
• Fonia A, Jackson K, Lereun C, et al. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol 2010;163(4):807-16
   PubMed Web of Science ®Google Scholar
• Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg 2005;24(1):52-7
   PubMedGoogle Scholar
• Reich K, Wu E, Mulani P, Gupta S. Direct and indirect economic burden of employees with moderate to severe psoriasis. Proceedings of the 68th Annual Meeting, American Academy of Dermatology; 5–9 March 2010; Miami Beach, FL, USA
   Google Scholar
• Han C, Lofland JH, Zhao N, Schenkel B. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol 2011;10(8):843-50
   PubMed Web of Science ®Google Scholar
• Hankin CS, Feldman SR, Szczotka A, et al. A cost comparison of treatments of moderate to severe psoriasis Drug Benefit Trends. 2005;17:200-14
   Google Scholar
• Leonardi C, Sobell J, Crowley J, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open label study. Br J Dermatol 2012;167(3):658-67
   PubMed Web of Science ®Google Scholar
• Lachaine J, Martel M, Langley R, Poulin YP. Health care resource utilization by patients with psoriasis. Proceedings of the 67th Annual Meeting, American Academy of Dermatology; 6–10 March 2009; San Francisco, CA, USA
   Google Scholar
• Poulin Y, Langley R, Teixeira HD, et al. Biologics in the treatment of psoriasis: clinical and economic overview. J Cutan Med Surg 2008;13:S49-57
   Google Scholar
• Rabinovich M, Fainaru M. Infliximab for the treatment of extensive plaque psoriasis – regulation, cost and reimbursement. Isr Med Assoc J 2003;5(11):817-18
   PubMedGoogle Scholar
• Finzi A, Mantovani L, Belisari A. The cost of hospital related care of patients with psoriasis in Italy based on the AISP study. J Eur Acad Dermatol Venereol 2001;15(4):320-4
   PubMedGoogle Scholar
• Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson Å. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden – a cross-sectional study. Eur J Dermatol 2012;22(2):238-45
   PubMedGoogle Scholar
• Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46(6):850-60
   PubMedGoogle Scholar
• Carter CT, Goren A, Naim A, Martin S. Psoriasis and psoriatic arthritis patient productivity burden in the United States. Proceedings of the 70th Annual Meeting, American Academy of Dermatology; 16–20 March 2012; San Diego, CA, USA
   Google Scholar
• Kulkarni A, Balkrishnan R, Camacho F, et al. Medication and health care service utilization related to depressive symptoms in older adults with psoriasis. J Drugs dermatol 2003;3(6):661-6
   Google Scholar
• Bhosle MJ, Feldman SR, Camacho FT, et al. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatol Treat 2006;17(5):294-301
   PubMed Web of Science ®Google Scholar
• Gunnarsson C, Chen J, Rizzo JA, et al. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. J Dermatol Treat 2012;23(4):240-54
   PubMed Web of Science ®Google Scholar
• Lin H-C, Lucas PT, Feldman SR, Balkrishnan R. Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. J Dermatol Treat 2012;23(3):196-202
   PubMed Web of Science ®Google Scholar
• Rich S, Russell MW, Feldman SR. Estimates of failure rates and direct medical costs associated with the use of systemic treatments and phototherapy in patients with psoriasis. 16th Annual Meeting, Academy of Managed Care Pharmacy; 31 March–3 April 2004; San Francisco, CA, USA
   Google Scholar
• Nelson AA, Pearce DJ, Fleischer AB Jr, et al. Infliximab for inpatient psoriasis management-is there a role? J Dermatol Treat 2005;16(5-6):314-18
   PubMed Web of Science ®Google Scholar
• Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol 2010;146(1):46-54
   PubMedGoogle Scholar
• Association AARD. A briefing report on autoimmune disease and AARDA: past, present and future. American Autoimmune Related Diseases Association; Eastpointe, MI, USA: 2010
   Google Scholar
• Hakkaart-van Roijen L, Verboom P, et al. The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis. Pharmacoeconomics 2001;19(5):599-608
   PubMedGoogle Scholar
• Schmitt-Egenolf M. Switching biologicals: switching TNFα antagonists in psoriasis treatment. Dermatology 2008;216(4):281-2
   PubMedGoogle Scholar
• American Academy of Dermatology. AAD. Available from: www.aad.org/mobile-psoriasis/
   Google Scholar
• Cimmino M. Epidemiology of psoriasis and psoriatic arthritis. Reumatismo 2011;59(Suppl 1):19-24
   Google Scholar